Image 1 of 4
Image 2 of 4
Image 3 of 4
Image 4 of 4
Packaging & supply options
Your format, your way.
The same research peptide, with a choice of accessories and supply formats. Here’s what each option includes.
BAC water
Vial kit
Lyophilised peptide vial with separately packaged, complimentary BAC water.
BAC water + syringes
Syringe kit
Lyophilised peptide vial, BAC water and syringes.
BAC water + pen
Injection pen kit
Lyophilised peptide vial, BAC water and an injection pen.
Pen + pen needles
Reconstituted pen
VIETNAM ONLYPeptide solution supplied in a pen at the stated concentration, with pen needles.
For laboratory research only. Not for human or veterinary use.
Everform Pharma · Compound profile
Tirzepatide.
Two pathways. A clearer picture.
An introduction to GIP and GLP-1 signalling, the research behind tirzepatide, and the product details worth checking.
What is tirzepatide?
Tirzepatide is a synthetic peptide that activates two hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Both are part of the body’s response to food, which helps explain the interest in tirzepatide across metabolic research. [1]
The useful starting point is its dual-receptor activity. Understanding those two targets gives a clearer foundation for reading about appetite, glucose regulation and body-weight studies.
How do the two pathways fit together?
GIP and GLP-1 are incretin hormones. Tirzepatide engages both receptor systems, rather than acting only at GLP-1 receptors. In prescription-drug studies, it influences glucose-dependent insulin release, appetite and food intake, and slows gastric emptying. [1]
GIP SIGNALLING
A receptor pathway involved in the insulin response to nutrients.
GLP-1 SIGNALLING
A receptor pathway involved in glucose regulation, appetite and gastric emptying.
Why researchers are interested
Different studies ask different questions. These are three useful themes for navigating the literature, rather than a list of promised outcomes.
| Research area | What studies examine |
|---|---|
| Body weight | Changes in body weight over time in defined clinical populations. |
| Glucose regulation | Changes in HbA1c and other measures of blood-glucose control. |
| Appetite & food intake | How incretin signalling relates to appetite and calorie intake. |
Research context: prescribing information, SURMOUNT-1 and SURPASS-2. [1–3]
What the clinical findings tell us
SURMOUNT-1 investigated weight management in adults with obesity, or overweight with a weight-related complication, without diabetes. Over 72 weeks, the tirzepatide groups had greater average weight reductions than the placebo group. [2]
SURPASS-2 studied adults with type 2 diabetes over 40 weeks. Tirzepatide produced larger average reductions in HbA1c and body weight than the semaglutide comparator used in that trial. [3]
These findings concern clinical trial medicines and study populations. They do not establish equivalent outcomes or suitability for an Everform research product.
Clinical effects also come with risks: gastrointestinal adverse effects were common in these trials. Prescription tirzepatide requires clinical assessment; a research vial is not a substitute for a prescribed medicine. [2] [3]
The Everform product, at a glance
Compound Tirzepatide
Labelled vial amount 20 mg
Base format Lyophilised peptide powder
Supply options See the format guide above
Everform Pharma is based in Da Nang, Vietnam. Use the format selector to choose your supply option, and check the product label for the full REF, expiry date and storage conditions.
When reviewing a COA, match it to the relevant product reference. Identity, chromatographic purity and measured peptide content answer different questions; a purity percentage alone is not a measurement of milligrams per vial.
A few useful distinctions
Is tirzepatide the same as semaglutide?
No. Tirzepatide activates GIP and GLP-1 receptors. Semaglutide acts at GLP-1 receptors. They are different compounds; comparisons should be read in the context of the specific study. [3]
Does “20 mg” describe a dose?
Here, 20 mg is the labelled amount of peptide in the vial. It is not an administration instruction or a recommended dose.
Where should I find storage information?
Follow the conditions on your actual product label. Lyophilised and reconstituted formats may have different requirements. Avoid applying prescription-brand shelf-life instructions to a different formulation.
References
[1] Lilly. Zepbound prescribing information: mechanism of action and pharmacodynamics.
Everform Pharma · Da Nang, Vietnam
Educational product information.
For laboratory research only.
Not for human or veterinary use.
